Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b

Shi QingFeng; Song JiKui; Zhang YingXin; Yuan JianGuo; Wang SiKui; Li QingFang; Zhao HongKui

Issue 12

Dec. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(12): 1285-1287+1300

PDF( 1127 KB)

Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b

Research funding:

Published Date: 2011-12-20

Abstract

Abstract

Objective To study the efficacy prediction and the activation of CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b.Methods 32 patients were given interferon alfa-2b 5 MU every other day for 24 weeks.PBMC were isolated from fresh peripheral blood of chronic severe hepatitis B patients by Ficoll-Hypaque density gradient centrifugation and cultured with plastic-adherence method.FACS was used to analyze the expression of the CD4+/CD8+T cells surface markers, including human leukocyte antigen-DR (HLA-DR) and CD69.Results At the end of treatment, HBV-DNA levels loss rates were 37% (12 cases) , including HBeAg seroconversion in 5 cases (16%) .In 8 cases (25%) HBV-DNA levels were decreased and 12 cases (37%) were ineffective.Although interferon alfa-2b had no effects on the ratio of CD4+/CD8+T cells in chronic severe hepatitis B patients, the expression of CD4+/CD8+T cells activators, such as CD69 and HLA-DR were upregulated, especially in negative HBV-DNA cases.At 1, 4, 12, 24 weeks, there was significant difference (P< 0.05) .Compared with the decreased and ineffective cases, CD69/HLA-DR expression rates in negative HBV-DNA cases were the lowest at 24 weeks (P< 0.05) .Conclusion Interferon alfa-2b can Up-regulate the expression of CD69/HLA-DR on CD4+/CD8+T cells.The activation of CD4+/CD8+T cells levels can predict the efficacy in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b.
- interferon alfa-2b,
- hepatitis B,
- chronic,
- hepatitis B e antigens,
- T-Lymphocytes,
- CD 69

FullText(HTML)

References(11)

References

[1]Lok AS, McMahon BJ.Chronic hepatitis B[J].Hepatology, 2007, 45 (2) :507-539.

[2]中华医学会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.

[3]Senturk H, Baysal B, Tahan V, et al.Long-term effect of in-terferon therapy in patients with HBeAg positive chronic hepati-tis B infection[J].Dig Dis Sci, 2011, 56 (1) :208-212.

[4]Bingfa X, Qinglin F, Hui H, et al.Anti-hepatitis B virus ac-tivity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo[J].Pharmacology, 2009, 83 (6) :323-332.

[5]De Veer MJ, Holko M, Frevel M, et al.FunctionM classifi-cation of interferon-stimulated genes identified using mi-croarrays[J].J Leukoc Biol, 2001, 69 (6) :912-920.

[6]Ye S, Guo Q, Tang JP, et al.Could2’5-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients?A pilot study[J].Clin Rheumatol, 2007, 26 (2) :186-l90.

[7]吴丹丹, 汪慧英.CD69在细胞活化、凋亡中的双向免疫调节作用[J].中国病理生理杂志, 2010, 26 (9) :1859-1862.

[8]杨晓静, 邹雄, 王谦, 等.慢性乙肝和肝癌患者HLA-DR抗原在外周血淋巴细胞亚群中的表达分析[J].上海免疫学杂志, 2003, 23 (1) :59.

[9]Risso A, Smilovich D, Capra MC, et al.CD69in resting and activated T lymphocytes.Itsassociation with a GTP binding protein and biochemical requirements for its expression[J].J Immunol, 1991, 146 (12) :4105-4114.

[10]Lim LC, Fiordalisi MN, Mantell JL, et al.A whole-blood assay for qualitative and semiquantitative measurements of CD69sur-face expression on CD4and CD8T lymphocytes using flow cy-tometry[J].Clin Diagn Lab Immunol, 1998, 5 (3) :392-398.

[11]Salgado FJ, Lojo J, Fernandez-Alonso CM, et al.Interleu-kin-dependent modulation of HLA-DR expression on CD4and CD8activated T cells[J].Immunol Cell Biol, 2002, 80 (2) :138-147.

Relative Articles

[1]	Ting MAO, Mingyi XU, Jiayi WANG. Characteristics of T cells in the liver tissues of mice with nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2025, 41(3): 461-468. doi: 10.12449/JCH250311
[2]	Shuang LI, Zherui LIU, Qi ZHAO, Yinying LU. Clinical research advances in chimeric antigen receptor T-cell therapy for primary liver cancer[J]. Journal of Clinical Hepatology, 2023, 39(5): 1019-1029. doi: 10.3969/j.issn.1001-5256.2023.05.004
[3]	Ziyi LI, Wanjie ZHANG, Fuchun WANG, Xiaorong MAO, Junfeng LI. Role of T lymphocytes in primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2926-2931. doi: 10.3969/j.issn.1001-5256.2023.12.026
[4]	Xue WEN, Yujing HE, Qianqian YUAN, Chuyi LI, Lixia LU, Xiaohui YU, Jiucong ZHANG. Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance[J]. Journal of Clinical Hepatology, 2023, 39(4): 810-817. doi: 10.3969/j.issn.1001-5256.2023.04.011
[5]	Huijuan FAN, Chun SONG. Expression of peripheral CD100 and its regulation to T lymphocytes function in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(1): 128-136. doi: 10.3969/j.issn.1001-5256.2023.01.019
[6]	Mengkui HAN, Jin LI, Xiaohua YANG. Function and regulatory mechanism of T lymphocytes in tumor immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(11): 2621-2626. doi: 10.3969/j.issn.1001-5256.2022.11.037
[7]	Wang HaoLiang, Deng GuoHong. Functional status of hepatitis B virus-specific T cells in patients with chronic hepatitis B virus infection:Exhausted or silenced?[J]. Journal of Clinical Hepatology, 2020, 36(5): 980-982. doi: 10.3969/j.issn.1001-5256.2020.05.005
[8]	Li Yu, Tian Ying, Yang XiaoMei, Cao NingJia, Li Zhu, Zhang Hong, Zhang XianJiao. Effect of thymosin α1 on the function of CD4+CD25+CD127dim/- regulatory T cells in chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2018, 34(5): 1011-1014. doi: 10.3969/j.issn.1001-5256.2018.05.017
[9]	Guo ChunXia, Li Jia, Xu CengLi, Guo Jie, Zhai Lu, Han Xu. Impact of HBV DNA detection methods on evaluating the clinical effect of PEG-IFNɑ-2b in treatment of HBeAg-positive chronic hepatitis B: a comparative analysis[J]. Journal of Clinical Hepatology, 2017, 33(4): 664-667. doi: 10.3969/j.issn.1001-5256.2017.04.013
[10]	Hou YuLi, Zhang YongHong, Zhao Yan. Immunological characteristics of tumor antigen specific T cells and their possible mechanisms in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(6): 1220-1224. doi: 10.3969/j.issn.1001-5256.2016.06.048
[11]	Li CaiDong, Chen XiLian, Tian PengFei, Li HuiJun, Wu Bin. Correlation analysis of percentages of T lymphocyte subsets and CD4~+CD25~+ regulatory T cells and HBV DNA level in peripheral blood of chronic hepatitis B patients[J]. Journal of Clinical Hepatology, 2015, 31(4): 541-545. doi: 10.3969/j.issn.1001-5256.2015.04.016
[12]	Xian YongChao, Cheng ShuQuan, Ni Hui, Huang ChengJun. Analysis of hepatic CD4~+,CD8~+,CD20~+,and CD57~+ T lymphocytes in chronic hepatitis B patients with different HBe Ag status[J]. Journal of Clinical Hepatology, 2015, 31(4): 546-550. doi: 10.3969/j.issn.1001-5256.2015.04.017
[13]	Cao Hui, Zhang Yang, Tan ShanZhong, Zhao Lei, Shen JianJun, Xiao Qian, Liang ZhongFeng, Jiang ShuLian. Relationship between percentages of T lymphocytes in peripheral blood and deficiency of vital qi in patients with HBV- ACLF[J]. Journal of Clinical Hepatology, 2014, 30(4): 320-323. doi: 10.3969/j.issn.1001-5256.2014.04.009
[14]	Zhao XiaoLing, Zhang YongGang. Clinical efficacy of ribavirin combined with different doses of interferon α- 2b in patients with chronic hepatitis C genotypes 2 and 3[J]. Journal of Clinical Hepatology, 2013, 29(10): 780-783. doi: 10.3969/j.issn.1001-5256.2013.10.014
[15]	Wu YinYa, Tan ShanZhong, Zhao Lei, Sun WeiWei, Shen JianJun, Liang ZhongFeng. The changes and value of the proportion of CD4+CD25+ regulatory T cells in HBeAg (+) and HBeAg (-) ASC in peripheral blood[J]. Journal of Clinical Hepatology, 2012, 28(3): 209-211.
[16]	Yan ShuangHuan, Cao ZhiChen. Changes in Toll-like receptor 4 expression on the surface of peripheral blood monocytes in patients with chronic hepatitis B during interferon treatment [J]. Journal of Clinical Hepatology, 2012, 28(11): 828-830.
[17]	Jiang ShuLian, Tan ShanZhong, Wen Jian. Role of CD4+CD25+ T regulatory cells in HBeAg seroconversion during interferon antiviral[J]. Journal of Clinical Hepatology, 2012, 28(7): 528-530.
[18]	Wang Xu, Yuan ChengMin, Wu AnZhao, Lu Yong, Zhao YuJuan. The observation of anti-viral effect of matrine combined with interferon α-2b on the chronic hepatitis B patients with mild transaminase elevations[J]. Journal of Clinical Hepatology, 2011, 27(5): 488-489+502.
[19]	Jin Rui, Zhang ShiBin, Bian XinQu, Lu ChengZhen, Liu ZhongSheng, Guo XinHui. Clinical study of IFNα-2b alone or in combination with lamivudine for HBeAg positive chronic hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(6): 617-619.
[20]	Huang AiChun, Wu JiZhou, Wu JianLin, Chen WuQing, Wei YingHua, Luo ShuangYan, Ning QiuYue, Li LanLan. The correlation between HLA-DRB114 and HLA-DRB115 alleles and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(4): 420-422.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3851) PDF downloads(708)

Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content